Human papillomavirus type 16 E7 protein presented by HLA-A*02:01 (HPV16 E7/HLA-A*02:01)

The **Human papillomavirus type 16 E7 protein presented by HLA-A*02:01** describes a specific immunogenic peptide derived from the E7 oncoprotein of HPV type 16, processed and displayed by the HLA-A*02:01 major histocompatibility complex (MHC) class I molecule on the surface of infected or transformed cells. This peptide–MHC complex is recognized by cytotoxic T lymphocytes as a foreign antigen, making it a critical target for immune-mediated therapies and vaccine development, especially against HPV16-related cancers such as cervical carcinoma. Therapeutic strategies include engineered T cell receptors, monoclonal antibodies, and peptide vaccines. Since the target requires both persistent HPV infection and the specific HLA-A*02:01 allele, it is highly selective but dependent on correct patient selection. Immunotherapeutic agents targeting this complex utilize the mechanism of direct immune activation against HPV-transformed cells expressing the E7 peptide in the context of HLA-A*02:01.

Other names

HPV16 E7–HLA-A*02:01 complexHPV16 E7 epitope presented by HLA-A2HPV16 E7 peptide–HLA-A*02:01 complexHPV16 E7–HLA-A2

Recruitment and activation of cytotoxic T lymphocytes against HPV16+ tumor cells through recognition of HPV16 E7 peptide presented on HLA-A*02:01; Engagement by engineered antibodies or TCR mimics to induce immune cell–mediated cytotoxicity